Announcer | The a16z Show Summary

1. Key Themes

China Has Structurally Surpassed the U.S. in Drug Innovation — And Almost Nobody Knows It

China's rise in biomedical innovation isn't incremental — it's a categorical shift that has already happened, yet hasn't penetrated mainstream awareness. The speed of the transition is staggering: from near-zero clinical trial activity to global leadership in under a decade.

"China is actually ahead of the U.S. now. And I'm going to show you some documentation of that. Some people haven't realized it yet. It hasn't really leaked to the press at this point. They don't realize that China is actually the top dog now, which upsets things. It changes a lot." — Cremieux Recueil 00:04:29

This lead isn't just in volume — it's in novelty. China is leading in first-ever phase one appearances for gene therapies, novel frontier drugs, antibody-based drugs, and small molecule drugs.

"In 2025, we had like 20 something new gene therapies that have never been done before entering phase one. And China had six times as many." — Cremieux Recueil 00:16:51

China's 2016 Regulatory Reforms Are the Blueprint the West Is Ignoring

The mechanism behind China's rise is not mysterious — it's a deliberate, well-documented set of policy reforms that systematically eliminated bureaucratic friction while preserving safety standards. The reforms include accepting overseas clinical data, parallel ethics committee approvals, the Market Authorization Holder (MAH) system, and dramatically shortened review timelines.

"Before the reforms, you can see the review backlog used to be like almost two years... And now it's 65 days is their target. And they're trying to get down even less than that. They're trying to do reviews in like 40 days." — Cremieux Recueil 00:31:05

The parallel IRB approval system alone is a transformative idea the U.S. has not adopted:

"If you are running a bunch of sites for your trial and one site in one region of the country approves the experiment, then every other site suddenly gets the same approval... One ethics committee already signed off." — Cremieux Recueil 00:24:33

China Solved the Drug Pricing Paradox — Lower Prices, Higher Corporate Profits, More Innovation

Perhaps the most counterintuitive finding in the entire episode: China's drug reimbursement negotiations actually increased pharmaceutical company profits while lowering drug prices and government expenditure. This is the opposite of how Western negotiations typically work.

"China says, well, no, we're going to make you profitable. We're actually going to make you money. If you are a firm that we are negotiating with and you lower those costs, we're going to help you sell more so that you don't have a reduction in your profits — so they become more profitable and we pay less money and everybody's just better off in general." — Cremieux Recueil 00:26:00

And it creates a virtuous cycle: the areas China targets with negotiation see the biggest increase in clinical trial activity, driving further competition, further price reduction, and further innovation.

"The clinical trial effort gets distributed to the areas that China is targeting... those things are often really expensive because they're often places where they have a lot of new drugs... They target them. They lower the price. They increase the quantity sold. And it leads to more effort in those spaces." — Cremieux Recueil 00:44:10

2. Contrarian Perspectives

China Is More Capitalist Than America in Pharma — And That's Why It's Winning

The intuitive assumption is that a communist/mixed-economy state would be worse at running efficient markets for innovation. The reality is the opposite: China has designed more market-aligned incentive structures in drug development than the U.S.

"It definitely is in some ways [more capitalist]. I'll actually get to some of those when I start the presentation." — Cremieux Recueil 00:07:03

"China is actually doing market design that is really effective... They figured out that part of why America innovates is because it pays so much, and they've exploited this mechanism and made themselves better off for it." — Cremieux Recueil 00:43:16

U.S. Pharmaceutical Returns Are Already Below the Cost of Capital — MFN Pricing Will Make It Worse

The conventional narrative is that U.S. drug companies are obscenely profitable and need to be reined in. The contrarian reality, backed by data, is that pharma returns are already insufficient to sustain the innovation pipeline — and Trump's Most Favored Nation pricing policy threatens to make this worse.

"The returns for pharmaceuticals are below the cost of capital... The pharmaceutical profits are actually taking a hit from MFN." — Cremieux Recueil 00:47:49

"If you actually are committed to doing it properly, you will do that. You will hurt those profits. And the profits are already too low to make this stuff self-financing." — Cremieux Recueil 00:48:18

Germline Gene Therapy Bans Are Scientifically Indefensible — and China Will Force a Reckoning

The U.S. bans gene therapies that make heritable changes, preventing permanent cures for genetic diseases. Cremieux argues this prohibition lacks sound justification and that competitive pressure from China will ultimately force a reversal.

"If we can cure a family of like a horrible debilitating disease for all time, why don't we? I think we're slowly coming around on this society and we're going to do that because China is going to do that in part. I think that might be like a little bit of our motivation to do that." — Cremieux Recueil 00:18:11

Scientific Fraud in the U.S. Has Cost Billions — China's Aggressive Prosecution May Give It a Research Quality Advantage

The idea that an authoritarian government would be better at policing scientific fraud than the U.S. is deeply counterintuitive. Yet Cremieux argues China's willingness to jail fraudsters and cut off their networks gives it a structural research quality advantage.

"I actually think China will get ahead in a lot of ways because they prosecute frauds and the government is like, once they've identified something as fraudulent, they're not going to fund it anymore... They're willing to do things that take like a lot of really quick actions." — Cremieux Recueil 00:39:24

The case in point: Eliezer Masliah, former head of the NIA's neuroscience division, whose fraudulent Alzheimer's research misdirected billions of dollars.

"He basically led to the misallocation of billions of dollars in money that went to like clinical trials and all this stuff... You spent all your level ups on bullshit. It's just terrible." — Cremieux Recueil 00:39:24

The U.S. Is Already Deregulating — But the Market Doesn't Know It

Cremieux makes a point that cuts against both the "nothing is changing" and the "DOGE is destroying everything" narratives: significant deregulation has already occurred in areas like stem cell therapies, but industry isn't acting on it because they're unaware.

"There's extensive stem cell deregulation that's happened, but nobody knows about it. So the effort being put into it by companies is like not there. They can do more stuff right now." — Cremieux Recueil 00:45:56

3. Companies Identified

Eli Lilly

Global pharmaceutical company known for GLP-1 drugs including dulaglutide and tirzepatide. Mentioned as a pioneer in innovative control arm trial design — using data from one trial as the control arm for another to reduce costs and enrollment burden.

"Eli Lilly has these two trials... they both have the same inclusion criteria and everybody in one trial is eligible to be in the other trial. So your control arm for your novel thing, you don't have to actually have a control arm. Just use the control data from that previous trial." — Cremieux Recueil 00:35:08

Gilead Sciences

Biopharmaceutical company. Cited as the pioneer of the hepatitis C cure and as an example of how Me Too drugs, when a competitor enters the market, can dramatically lower net drug prices — a market dynamic with broad policy implications.

"It was either Amgen or Gilead did it first... then the actual price on the drug that is paid by the insurers, the net price, came down immediately. Because when you have like 10 drugs in a space, the cost of the drug is like 90% down." — Cremieux Recueil 00:14:06

Chan Zuckerberg Initiative

Philanthropic science organization funded by Mark Zuckerberg and Priscilla Chan. Mentioned as working on computational biology that may eventually reduce the need for certain clinical trial work through cell, organ, and systems-level simulation.

"This is what Chan Zuckerberg Initiative is working on. They're trying to figure out a computational bio on the cell level and then on the organ level and then the system level." — Theo Jaffee 00:51:52

4. People Identified

Cremieux Recueil

Independent researcher specializing in psychometrics, econometrics, and cliometrics. Invited for his deep empirical work on China's clinical trial reforms and their implications for global drug development. Presents a rare, data-driven view of a trend the mainstream press has not yet grasped.

"China is actually ahead of the U.S. now. And I'm going to show you some documentation of that. Some people haven't realized it yet. It hasn't really leaked to the press at this point." — Cremieux Recueil 00:04:29

Sholto David

Independent scientific integrity researcher. Briefly but importantly flagged as someone who single-handedly filed a qui tam case against Dana Farber for fabricated research images. Represents a new model of decentralized scientific fraud detection with major implications for research funding allocation.

"There's like one guy filed his own case against Dana Farber for fake images and stuff. Sholto David... bring him on. I think he'll have a lot to say about fraud and stuff." — Cremieux Recueil 00:38:57

Eliezer Masliah

Former head of NIA's neuroscience division; described as the top-cited global researcher on Alzheimer's and Parkinson's. Flagged as a major cautionary tale — his fraudulent research caused billions in misallocated funding and sent the entire field down a dead-end research path.

"He basically led to the misallocation of billions of dollars in money that went to like clinical trials and all this stuff... Tons of people spent time trying to replicate his stuff and it just did not work." — Cremieux Recueil 00:39:08

Vivek Ramaswamy

Entrepreneur and politician. Mentioned as an example of a drug repurposing business model — identifying abandoned drugs with promising secondary endpoints, acquiring them cheaply, and repurposing them for new indications.

"Basically he finds drugs that have been abandoned and he looks at them and he goes, oh, this actually helped this like secondary endpoint. Let's go pick up that drug, buy it for cheap because it was abandoned. And then repurpose it for this other thing." — Cremieux Recueil 00:11:00

5. Operating Insights

The Parallel Ethics Committee Approval Model Should Be Adopted Immediately by Any Multi-Site Trial Operator

For anyone running or investing in clinical-stage biotech: the single biggest operational drag in multi-site trials is redundant IRB/ethics committee review. China's model — where one site's approval propagates to all sites — eliminates this. Companies running U.S. trials should explore whether any existing FDA pathways (e.g., central IRBs under the 2018 Common Rule revisions) approximate this, and advocate loudly for full adoption.

"If you are running a bunch of sites for your trial and one site in one region of the country approves the experiment, then every other site suddenly gets the same approval. That's awesome. One ethics committee already signed off." — Cremieux Recueil 00:24:33

Innovative Control Arms Are a Cost-Reduction Lever Available Now — But Underused in the U.S.

For biotech operators: using external or historical control arm data (when eligibility criteria match) can dramatically reduce trial costs by eliminating redundant placebo enrollment and monitoring. This is already being deployed in China at scale and is supported by emerging FDA guidance on Bayesian and adaptive trial designs.

"You don't have to like enlist so many people. You can save money by not running the placebo thing again, because producing placebo drug is a non-trivial cost. And monitoring those people is a non-trivial administrative bit of overhead. You can cut that out entirely." — Cremieux Recueil 00:35:38

The Information Arbitrage on U.S. Deregulation Is Real and Actionable Right Now

There is a documented gap between what has already been deregulated in the U.S. (particularly in stem cell therapies) and what the industry believes is permitted. The first movers who map this gap and act on it will capture asymmetric value.

"There's extensive stem cell deregulation that's happened, but nobody knows about it. So the effort being put into it by companies is like not there. They can do more stuff right now." — Cremieux Recueil 00:45:56

6. Overlooked Insights

China Running U.S. Clinical Trials Is Already Happening — and Creates an Existential Dependency Risk

This was mentioned almost in passing, but it is a massive structural vulnerability hiding in plain sight. U.S. pharma companies are already beginning to run their trials in China because it is cheaper and easier. If this trend continues, the U.S. could find itself dependent on Chinese trial infrastructure for its own drug pipeline — at which point China could sever access and cripple U.S. pharmaceutical development entirely, without firing a shot.

"We're going to make all our trials Chinese because it's easier to run them there... But if they stop us, if they cut us off, then China might just be able to keep pushing ahead because they run cheaper trials and they'll be able to cut us off entirely. And we might just lose an edge entirely and like not have any way to catch up." — Cremieux Recueil 00:51:18

This is the clinical trial equivalent of semiconductor fab dependency on TSMC — a concentration risk that is forming right now, largely unnoticed, with potentially catastrophic strategic consequences.

China's Negotiation Model Increases Volume to Offset Price Cuts — This Is a Replicable Market Design Principle

Buried in the pricing discussion is a generalizable insight about market design: when you negotiate price down and simultaneously guarantee volume increase, you can make suppliers better off while paying less. This is not just a pharma insight — it's a procurement and market design principle applicable across industries. The key is that the buyer (China's government) has the market power and distribution infrastructure to credibly commit to volume. Any large platform, government, or aggregator with distribution leverage could replicate this model.

"To recap it, they lower the prices. They increase the volume sold. The revenue goes up. The companies end up better off. And there are no spillovers. It's goddamn amazing." — Cremieux Recueil 00:43:41